Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Redox-related genetic and biological ageing signals in rapid pain progression of knee osteoarthritis: a hypothesis-generating analysis in the osteoarthritis initiative

  • Blanco García, Francisco J
  • Oreiro Villar, Natividad
  • Vázquez-García, Jorge
  • Morano Torres, Antonio
  • Relaño, Sara
  • Martínez-Sotodosos, Laura
  • Noriega-Cobo, Diana M.
  • Otero Fariña, Fátima
  • Mosquera Rey, Alejandro
  • Fernández, José L.
  • Rego-Pérez, I.
[Abstract] Rapid pain progression in knee osteoarthritis (OA) is heterogeneous and may reflect redox-related mechanisms. We performed an exploratory analysis in Osteoarthritis Initiative (OAI) participants, combining nuclear genome-wide association, mitochondrial DNA (mtDNA) haplogroups, and leukocyte telomere length. Rapid pain progression was defined using the rescaled Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain (0-100) within 24-month windows. An additive genome-wide association study (GWAS) in 2946 participants tested 7,762,204 imputed variants, adjusting for age, sex, body mass index (BMI) and three principal components. Haplogroups were analysed in 3357 participants, and telomere length (telomere-to-single-copy gene, T/S, ratio) was analysed in 301 participants. No variant reached genome-wide significance (p < 5 × 10-8), but six loci were suggestive (p < 5 × 10-6), with minimal inflation (λ = 0.995). mtDNA haplogroup H was nominally associated with rapid pain progression (odds ratio, OR = 1.179, p = 0.023). Rapid pain progressors had shorter baseline telomeres (0.825 ± 0.268 vs. 0.985 ± 0.375; p < 0.001), and telomere length was inversely associated with progression (OR per 1-unit T/S = 0.260, p = 0.007). These preliminary, hypothesis-generating findings are compatible with a redox-related interpretation of rapid pain progression and require external validation in independent cohorts, while providing candidates for future mechanistic studies., This study has been funded by Instituto de Salud Carlos III (ISCIII), through the projects RD21/0002/0009, RD24/0007/0026, PMP22/00101, PMPTA22/00115, PI22/01155 and PI23/00913, and co-funded by the European Union. This work was also funded by grants IN607A 2021/07 and IN607D 2021/13 from Axencia Galega de Innovación-Xunta de Galicia. I.R.-P. is supported by Contrato Miguel Servet-II Fondo de Investigación Sanitaria (CPII17/00026) SERGAS-stabilised. J.V.-G. is supported by grant IN606A 2022/048 from Xunta de Galicia, Spain. A.M.-T. is supported by Contrato Predoctoral de Formación en Investigación en Salud (FI24/00023) from Instituto de Salud Carlos III. L.M.-S. is supported by contrato i-PFIS from Instituto de Salud Carlos III (IFI24/00042). This work was also funded by Pfizer and Eli Lilly and Company through the 3rd Global Awards for Advancing Chronic Pain Research, ADVANCE (grant ID#64122119). This study has been also supported by an Open Access Articles grant from Fundación Pública Galega de Investigación Biomédica INIBIC.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Predicting total knee replacement in knee osteoarthritis using a machine learning-guided approach in patients of the Osteoarthritis Initiative (OAI)

  • Blanco García, Francisco J
  • Oreiro Villar, Natividad
  • Vázquez-García, Jorge
  • Morano Torres, Antonio
  • Balboa-Barreiro, Vanesa
  • Rodríguez-Valle, Isabel
  • Relaño, Sara
  • Veronese, Nicola
  • de Andrés, María C.
  • Rego-Pérez, I.
[Abstract] Objective To develop a pragmatic model to predict total knee replacement (TKR) in knee osteoarthritis using non-imaging clinical, genetic and lifestyle data with machine learning (ML)-guided feature selection. Methods We analysed 3790 Osteoarthritis Initiative participants. Nested ML feature selection on the training set identified 15 informative variables. Classifiers were benchmarked, then a multivariable logistic regression was fit on the full cohort. Performance was summarised by discrimination (area under the curve (AUC) with 95% CI) and calibration (Brier score). To assess the incremental value of genetics, we refit an otherwise identical clinical model excluding the Polygenic Risk Score (PRS) and compared specificity at fixed sensitivities using Bonferroni-adjusted McNemar tests. A prespecified analysis examined performance by baseline Kellgren-Lawrence (KL) grade (KL 0–1 vs KL ≥2). Results On the test set, classifier AUCs ranged 0.716–0.748, with Elastic Net and XGBoost performing best. The final logistic model fit on the full cohort achieved AUC 0.765 (95% CI 0.736 to 0.793) with acceptable calibration (Brier 0.097). Performance remained robust by disease stage, with higher discrimination in pre-radiographic knees (KL 0–1: AUC 0.827) and moderate discrimination in KL ≥2 (AUC 0.720); decile plots indicated broadly aligned observed versus predicted risks. PRS added modest, statistically significant gains in specificity at several fixed sensitivities without materially changing AUC. Conclusions We present a pragmatic, non-imaging, ML-informed model that predicts TKR with clinically acceptable discrimination and calibration using routinely collected data. This framework provides a practical basis for individualised risk stratification and decision support without reliance on imaging., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects RD21/0002/0009, RD24/0007/0026, PMP22/00101, PMPTA22/00115, PI17/00210, PI22/01165, PI22/01155 and PI23/00913 and co-founded by the European Union. This work was also funded by grants IN607A 2021/07 and IN607D 2021/13 from Axencia Galega de Innovación-Xunta de Galicia. IRP is supported by Contrato Miguel Servet-II Fondo de Investigación Sanitaria (CPII17/00026) SERGAS-stabilized. JVG is supported by grant IN606A 2022/048 from Xunta de Galicia, Spain. This work was also funded by Pfizer and Elli Lilly and Company through the Third Global Awards for Advancing Chronic Pain Research, ADVANCE (grant ID#64122119). This study has been also supported by an Open Access Articles grant from Fundación Pública Galega de Investigación Biomédica INIBIC.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Proteomic profiling of human synovial fluid reveals AKR1C1 as a biomarker of osteoarthritis severity

  • Fernández-Puente, Patricia
  • Paz González, Rocío
  • Calamia, Valentina
  • Picchi, Florencia
  • Quaranta, Patricia
  • Lourido Salas, Lucía María
  • Riva Mendoza, Selva
  • Lotz, Martin
  • Blanco García, Francisco J
  • Ruiz-Romero, Cristina
[Abstract] Pathological changes in the knee joint are reflected in the protein composition of synovial fluid (SF), which is altered in osteoarthritis (OA) and may serve as a source of biomarkers. This study used label-free quantification proteomics to analyze SF protein profiles from individuals with varying grades of cartilage damage and healthy controls. SF samples (n = 61) from healthy knees (grade 0) and OA-affected joints (grades I-IV, Outerbridge score) were analyzed using LC-MS/MS. Feature selection was performed with the Jonckheere-Terpstra nonparametric test. Candidate biomarkers were validated by ELISA in an independent cohort (n = 51), with OA severity graded according to the Kellgren-Lawrence (K/L) scale. Using this approach, nine proteins were significantly differentially expressed between OA and control samples (p < 0.01), showing higher levels in early OA stages compared to moderate and late disease (p < 0.05). Among these, aldo-keto reductase family 1 member C1 (AKR1C1), a protein involved in oxidative stress and autophagy, positively correlated with OA severity in both cohorts. These findings highlight several protein biomarkers with potential utility in early OA diagnosis and monitoring disease progression. Notably, AKR1C1 emerges as a promising diagnostic and prognostic biomarker, warranting further investigation., This work has been funded by Instituto de Salud Carlo s III (ISCIII) through the projects PI20/00793, PI20/01409, PI22/01155, and PI23/00818, and cofunded by the European Union, and also by the grant RD21/0002/0009 financed by Instituto de Salud Carlos III─European Union─NextGenerationEU─Plan de Recuperación transformación y resiliencia. This study has been also supported by grants IN607A2021/07 and IN607D2020/10 from Xunta de Galicia. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII). VC is supported by RICORS-REI RD21/0002/0009.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Integrated Serum Proteomics and Autoantibody Analyses Reveal a Biomarker Signature Predictive of Flare During Biologic Tapering in Rheumatoid Arthritis

  • Blanco García, Francisco J
  • Quaranta, Patricia
  • Domínguez-Guerrero, Pablo
  • Calamia, Valentina
  • Fernández-Puente, Patricia
  • Paz González, Rocío
  • Balboa-Barreiro, Vanesa
  • Noriega-Cobo, Diana M.
  • Galindo, Laura
  • Acasuso, Belén
  • Oreiro Villar, Natividad
  • Rojo, Ricardo
  • Lourido, Lucía
  • Ruiz-Romero, Cristina
[Abstract] Background: Reliable biomarkers predicting which patients with rheumatoid arthritis (RA) can safely undergo biologic tapering are currently lacking. This study aimed to identify circulating protein biomarkers predictive of flare during biologic disease-modifying anti-rheumatic drug tapering in RA. Methods: Baseline serum samples from patients with RA in sustained remission enrolled in the Biologic Optimisation (OPTIBIO) clinical trial were analysed using a two-stage design comprising an exploratory mass spectrometry in a discovery sample subset (n=44, 22 in the optimisation arm and 22 in the control arm), followed by ELISA validation of selected protein biomarkers and anti-cytokine autoantibody profiling in the full cohort (n=194). The primary outcome was a disease flare during follow-up. Results: During follow-up, disease flare occurred in 46.4% of patients in the optimisation arm and 30.9% in the control arm. Within the discovery subset of the optimisation arm, 87 proteins were differentially abundant between patients who flared and those who remained in remission. V-set immunoglobulin-domain-containing 4 (VSIG4) was validated as a biomarker associated with increased flare risk while anti-interferon-γ (anti-IFNγ) autoantibodies were also independently associated with flare. A combined model integrating VSIG4, anti-IFNγ and Disease Activity Score 28-joint count using C reactive protein improved discrimination compared with the clinical model alone (area under the curve (AUC) 0.760 vs 0.666) and showed higher sensitivity and greater potential clinical utility in decision curve analysis. In a secondary exploratory subgroup of patients with prolonged remission, predictive performance further improved (AUC 0.839). Conclusion: These findings identify a promising protein biomarker signature associated with flare during biologic tapering in RA, supporting biomarker-guided risk stratification in treatment optimisation strategies. External validation is required before clinical implementation., This work was supported by the Instituto de Salud Carlos III (ISCIII) through the projects PI20/00793, PI22/01155, PMP22/00101 and PI23/00818 (to FJB and CRR) and co-funded by the European Union. Additional funding was provided by Xunta de Galicia (grants IN607D2020/10, IN607A2021/07, and IN607A2025/11). LL was supported by a Sara Borrell Fellowship (CD19/00229). VC is supported by grant RD24/00070026, funded by the Carlos III Health Institute (ISCIII) and co-financed by the European Union. RPG is supported by Programa de axudas á etapa posdoutoral from Xunta de Galicia (IN606B-2024.22). The Biomedical Research Networking Center (CIBER) is an initiative of ISCIII (CB06/01/0040). This study has been also supported by an Open Access Articles grant from Fundación Pública Galega de Investigación Biomédica INIBIC.